Buy or sell 23andMe stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

23andMe Stock

Human Genome Research



Notable Investors

Sequoia Capital


Mountain View CA, US

Total Funding


About 23andMe Stock

23andMe, named after the number of chromosome pairs in humans, is a consumer genetics and research company. Co-founded by Linda Avey and Anne Wojcicki, 23andMe has plans to make the human genome searchable. The company aims to help people understand what their genes mean by indexing the genes and highlighting significant findings. 23andMe allows its customers to study their ancestry, genealogy, and inherited traits by analyzing their DNA from saliva samples. The company also markets to researchers and scientists, for whom they provide categorized and searchable data.

23andMe was founded in 2006 in the San Francisco Bay Area.

Source: 23andMe


Funding History

April 2007$9.0M
April 2009$27.8M
November 2010$31.2M
December 2012$58.4M
June 2015$115M
August 2017$250M
July 2018$385M


Co-Founder & Chief Executive Officer

Anne Wojcicki

Chief Financial Officer

Steve Schoch


23andMe’s Growth Slows

Wall Streets Journal - Feb, 8 2019

23andMe Responds: Empowering Consumers

New York Times - Feb, 5 2019

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from 23andMe or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 190K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: